Press Releases Awakn Life Sciences Corp.

Equities

AWKN

CA05455W1086

Market Closed - Canadian Securities Exchange Other stock markets 03:31:31 2024-05-31 pm EDT			5-day change	1st Jan Change
0.145 ^CAD	-25.64%		-25.64%	-.--%

Apr. 03	Awakn Life Sciences Corp. Announces Launch of Licensing Partnership Agreement with Rivus Wellness and Research Institute	CI
Apr. 03	Awakn Life Sciences Corp. announced that it expects to receive CAD 1 million in funding	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

CSE Bulletin: Reinstatement - Awakn Life Sciences Corp. (AWKN)	May. 31	NE
CSE Bulletin: Suspensions - AWKN, BHCC, BZAM, GLOW, VTAL, JKPT, MEAL,VFI.X, STHZ	May. 08	NE
Canadian Investment Regulatory Organization Trading Halt - AWKN	May. 08	AQ
Awakn Life Sciences Discusses Filing of Financial Statements	May. 02	NE
Awakn Life Sciences Announces Closing of Tranche of Private Placement	Apr. 17	NE
Awakn Life Sciences Announces Launch of Licensing Partnership Agreement with Oklahoma Based Clinic	Apr. 03	NE
Canadian Securities Exchange Reports February 2024 Performance Figures	Mar. 15	NE
CSE Bulletin: New Listing - Awakn Life Sciences Corp. (AWKN)	Feb. 12	NE
Awakn Life Sciences Announces Listing on the Canadian Securities Exchange	Feb. 12	NE
Awakn Life Sciences Announces Conditional Approval of CSE Listing	Feb. 05	NE
Awakn Life Sciences Completes Successful Investigative Study to Establish Dissociative Effect of a Proprietary Sublingual S-Ketamine Oral Thin Film Formulation in Harmful Drinkers	Jan. 24	NE
Awakn Life Sciences Enters Global Licensing Agreement For Proprietary Sublingual S-Ketamine Formulation With LTS	Dec. 20	NE
Awakn Life Sciences Provides Corporate Update	Dec. 15	NE
Awakn Life Sciences Receives Regulatory and Ethical Approval for Phase III Clinical Trial of AWKN-P001	Nov. 15	NE
Awakn Life Sciences Announces Receipt of Notice of Non-Compliance with Cboe Exchange Continued Listing Requirements	Nov. 10	NE
Awakn Life Sciences Engages Orphan Insight Ltd. to Advance Market Access, Pricing, and Reimbursement Strategies for AWKN-P001 Targeting Severe Alcohol Use Disorder	23-10-31	NE
Awakn Life Sciences : AWKN Testing	23-10-19	PU
Awakn Life Sciences : AWKN.NE)	23-10-16	PU
Awakn Life Sciences Completes MDMA Zydis(R) ODT Feasibility Study	23-10-04	NE
Awakn Life Sciences Provides Corporate Update	23-09-14	NE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Awakn Life Sciences Corp.

Equities

AWKN

CA05455W1086

Press Releases

Filters